Description: In the past months, as COVID-19 has forced the reduced activity in the U.S. economy there has been some very substantial, but varied effects on the U.S. healthcare system. There is a lot of potential for confusion amongst providers and patients with regards to decisions related to which services ought to be rendered and which ought to be deferred. Two specific agencies – the Centers for Medicare and Medicaid Services (CMS), and the American College of Surgeons (ACS) have put together some guidance to add more clarity towards what types of services should be provided and what types ought to be deferred. In addition, this paper includes a discussion on what types of services are most likely to be deferred, and which ones will accrue pent-up demand to be released when many of the deferred services become available again.

Description: The SOA has translated four of its AIT report summaries into both Traditional and Simplified Chinese. They are “Behavioral Science”, “Big Data and the Future Actuary”, “Cancer Genomics”, and “Cloud Computing and Machine Learning Uses in the Actuarial Profession.

Description: Social Determinants of Health (SDOH) include the social and physical conditions in which people are born, live and work on a daily basis. This project advances a growing body of literature to inform the ongoing optimization of population health and payment models.

Description: This is a brief report that summarizes recent changes in the prevalent medical loss ratio methodologies and also looks at some of the more recent experience of health insurers that filed medical loss ratio reports.

Description: The COVID-19 pandemic will have a lasting impression on all forms of life, annuity, and A&H insurance. Individual and group disability insurance are no exception. Examine how U.S. group and individual disability insurers have been impacted by the pandemic and how they are preparing for an uncertain future. Oliver Wyman will team up with experts from the insurance industry to discuss insights on the impact of COVID-19 on disability insurance, including results from Oliver Wyman’s 2022 industry survey. Learn about the past, current, and future expected impacts of COVID-19 on: - Claim experience (including mortality, incidence, recovery and SSDI offsets) - Reserving - Scenario testing - Insurer operations (e.g., claims adjudication, recertification) - Sales and persistency By attending this session, you will be able to: - Understand how disability insurers have been impacted by the pandemic across multiple facets. - Identify where and how U.S. disability insurance carriers are adapting to the new and evolving environment. - Discover how carriers see disability insurance evolving as the COVID-19 pandemic continues.

Description: The U.S. health care system continues to have its problems. It costs too much and even with public policy developments we are not meeting the desired objectives. What's next? What else can we do? Discuss some of the emerging ideas that are being pursued and the likelihood of their success at solving our collective problem.

Description: The Society of Actuaries (“SOA”) Research Institute is the research arm of the SOA, providing objective, data-driven research that brings together tried and true practices and future-focused approaches to address societal challenges and business needs. The Institute provides trusted knowledge, extensive experience and new technologies to help effectively identify, predict and manage risks.

Description: The SOA is seeking researchers to explore considerations within the LGBTQ+ community impacting employer-based health benefit designs. Review details on the background, research objectives, proposal requirements, selection process, submission guidelines, and project conditions.

Description: There is a big wave of changes coming to the pharmacy market. The extent is not yet fully known, but there are trends we can follow that help us predict. Biosimilar uptake is key to driving savings, but it can take a while to ramp up. Biosimilars bring competition, and this coming wave will bring unprecedented Biosimilar competition.

Description: The 2013 Individual Disability Income Valuation Table (2013 IDIVT) approved by the NAIC as the new statutory minimum reserve morbidity basis.